Loading...
XNAS
TXG
Market cap1.30bUSD
Jun 16, Last price  
11.01USD
1D
-1.56%
1Q
0.73%
IPO
-80.07%
Name

10X Genomics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
2.25
EPS
—
Div Yield, %
—
Shrs. gr., 5y
25.24%
Rev. gr., 5y
19.96%
Revenues
611m
-1.28%
71,085,000146,313,000245,893,000298,845,000490,490,000516,409,000618,727,000610,785,000
Net income
-183m
L-28.41%
-18,762,000-112,485,000-31,251,000-542,731,000-58,223,000-166,000,000-255,099,000-182,627,000
CFO
7m
P
-10,699,000-76,409,00034,627,000-217,898,000-21,373,000-33,606,000-15,197,0006,664,000
Earnings
Aug 06, 2025

Profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
URL
https://www.10xgenomics.com/
IPO date
Sep 12, 2019
Employees
1,243
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
610,785
-1.28%
618,727
19.81%
516,409
5.28%
Cost of revenue
461,001
823,076
684,353
Unusual Expense (Income)
NOPBT
149,784
(204,349)
(167,944)
NOPBT Margin
24.52%
Operating Taxes
4,927
6,336
4,029
Tax Rate
3.29%
NOPAT
144,857
(210,685)
(171,973)
Net income
(182,627)
-28.41%
(255,099)
53.67%
(166,000)
185.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
19,483
21,226
BB yield
-0.30%
-0.51%
Debt
Debt current
9,286
23,042
9,037
Long-term debt
155,940
263,068
181,315
Deferred revenue
8,814
3,165
Other long-term liabilities
17,542
(79,574)
6,141
Net debt
(228,176)
(102,585)
(244,606)
Cash flow
Cash from operating activities
6,664
(15,197)
(33,606)
CAPEX
(12,393)
(48,601)
(131,661)
Cash from investing activities
(32,631)
133,492
(350,887)
Cash from financing activities
10,914
13,669
15,817
FCF
200,533
(224,165)
(326,353)
Balance
Cash
393,402
388,695
429,984
Long term investments
4,974
Excess cash
362,863
357,759
409,138
Stockholders' equity
(1,467,538)
(1,284,847)
(1,033,654)
Invested Capital
2,277,827
2,229,719
1,939,800
ROIC
6.43%
ROCE
18.49%
EV
Common stock shares outstanding
120,452
117,165
113,859
Price
14.36
-74.34%
55.96
53.57%
36.44
-75.54%
Market cap
1,729,684
-73.62%
6,556,555
58.03%
4,149,010
-74.76%
EV
1,501,508
6,453,970
3,904,404
EBITDA
193,492
(160,730)
(134,938)
EV/EBITDA
7.76
Interest
4
33
476
Interest/NOPBT
0.00%